Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
BACKGROUND
Previous data suggested that serum levels of soluble mesothelin (SM) are related to tumor size and may have prognostic significance in malignant pleural mesothelioma (MPM).


OBJECTIVE
We tested the hypothesis that this marker could also be useful for monitoring response to treatment.


METHODS
Serial measurements of SM were determined in 40 patients diagnosed with MPM and subjected to gene-transfer therapy using intrapleural infusion of an adenoviral vector expressing human IFN-beta or conventional treatment (mainly chemotherapy).


RESULTS
In patients with baseline SM levels greater than 1 nM/L and disease progression after therapy, SM levels increased by 2.1 nM/L at two, 5.2 nM/L at four and 1.3 nM/L at 6 months. Patients with initial SM below 1 nM/L had a similar but more moderate increase of SM over time. Patients who responded to treatment or were considered stable had an initial small decrease of SM followed by a return to baseline values after 6 months of follow-up. In patients with baseline SM levels greater than 1 nM/L, increasing levels were associated with a significantly shorter median survival than in patients with stable or decreasing SM levels (4.4 vs. 27.7 months; P = 0.012).


CONCLUSIONS
Increasing serum levels of SM were associated with disease progression and worse outcome, whereas stable or decreasing values suggested response to treatment. If confirmed in larger series, SM could be used to monitor patients with malignant pleural mesothelioma under treatment.
Grigoriu
Bogdan D
BD
INSERM Unit 774, Institut Pasteur of Lille, Lille, France.
Chahine
Bachar
B
Vachani
Anil
A
Gey
Thomas
T
Conti
Massimo
M
Sterman
Daniel H
DH
Marchandise
Genevieve
G
Porte
Henri
H
Albelda
Steven M
SM
Scherpereel
Arnaud
A
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D016899:Interferon-beta / Q000096:biosynthesis / Q000235:genetics; D008297:Male; D008654:Mesothelioma / Q000097:blood* / Q000235:genetics / Q000628:therapy; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000097:blood* / Q000235:genetics / Q000628:therapy; D011379:Prognosis; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D016899:Interferon-beta